2 files

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

posted on 2022-12-18, 19:28 authored by Adis Journals on behalf of:, Amy S. Paller, Elaine C Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit, Randy Prescilla

The above Key Points and Plain Language Summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). 

© The authors, CC-BY-NC 2022